Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

DCM vs NMR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

NMR Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 9–1 Matrix Metrics)

NMR Overall Winner 6-Pillar Tally: DCM 0 – 5 NMR (1 Tie) Matrix Metrics: DCM 1 – 9 NMR

As of Nov 20, 2026, Nomura Holdings, Inc (NMR) is the stronger overall head-to-head candidate over DCM (DCM) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). DCM carries a Unified Composite Score of 48.8/100 (HOLD) at $2.82 (N/M Forward P/E, N/A operating margin), whereas NMR carries 35.0/100 (SELL) at $8.51 (11.4x Forward P/E, 25.1% operating margin).

  • Composite vs. Pillar Nuance: While DCM currently prints a higher short-term Unified Composite Score (48.8/100 HOLD vs. NMR 35.0/100 SELL), NMR captures the overall institutional head-to-head verdict (9–1 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (25.1% vs. N/A operating margin) and revenue trajectory (+17.9% vs. N/A YoY).
  • Technical & Structure Timing Caution: DCM trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI N/A); meanwhile NMR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 30.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About DCM vs NMR
DCM US Equity
DCM
Institutional Equity
$2.82
-6.62% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol N/A
Unified Composite Score
48.8 / 100 HOLD
Tech 50.0 Fund 50.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Trend telemetry aligned with daily close.
RSI-14: N/A · SMA20: N/A · SMA50: N/A
NMR NYSE Head-to-Head Winner
Nomura Holdings, Inc
Security Brokers, Dealers & Flotation Companies
$8.51
-5.86% 1D
Market Cap $26.4B
TTM Revenue $14.9B
Forward P/E 11.4x
Beta / 30D Vol 1.04β · 34% Vol
Unified Composite Score
35.0 / 100 SELL
Tech 13.0 Fund 35.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -3.0%), weak momentum, RSI 30
RSI-14: 30.4 · SMA20: $9.38 · SMA50: $9.58

6-Pillar Scorecard Institutional Category Breakdown (DCM 0 – 5 NMR)

Columns: Metric · DCM · NMR
1. Valuation Multiples NMR
Forward P/E N/M 11.4x
Trailing P/E N/M 10.4x
PEG Ratio N/M 0.81x
EV / Revenue N/M 1.8x
2. Growth & Scale NMR
Revenue Growth (YoY) N/A +17.9%
Earnings Growth (YoY) N/A +13.6%
TTM Revenue (USD) N/A $14.9B
Market Cap N/A $26.4B
3. Profitability & Quality NMR
Gross Margin N/A 77.4%
Operating Margin N/A 25.1%
Net Profit Margin N/A 17.1%
Return on Equity (ROE) N/A 11.5%
4. Balance Sheet & Cash Flow NMR
Cash Generation (TTM) N/A N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage N/A ROE $8.17 Book/Sh · 11.5% ROE
Dividend Yield None (0.00%) 1.66%
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) 30.7% (<1st %ile)
Put/Call OI Skew N/A Thin ADR Chain
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat NMR
OpEx & R&D Intensity N/A 52.3% of Rev ($7.77B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Scale & Operating Efficiency Moat
Supply-Chain Role Institutional Equity Operator Capital Markets Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: DCM (1) vs NMR (9)
Institutional Metric DCM NMR Criterion Row Edge
Market Capitalization
Scale
N/A $26.4B Larger Scale NMR
Trailing P/E Ratio
Valuation
N/M 10.4x Lower Multiple NMR
Forward P/E Ratio
Valuation
N/M 11.4x Lower Multiple NMR
Revenue Growth (YoY)
Growth
N/A +17.9% Higher Growth NMR
Operating Margin (TTM)
Profitability
N/A 25.1% Higher Margin NMR
Net Profit Margin
Profitability
N/A 17.1% Higher Margin NMR
Return on Equity (ROE)
Capital Efficiency
N/A 11.5% Higher ROE NMR
52-Week Range Position
Momentum
0% ($3–$5) 40% ($7–$11) Stronger Trend NMR
Beta / 30D Volatility
Risk Regime
N/A 1.04β · 34% Vol Lower Realized Risk NMR
Unified Institutional Score
Composite Signal
48.8 / 100 (HOLD) 35.0 / 100 (SELL) Higher Composite DCM
Trailing 12M Revenue (USD)
Operating Scale
N/A $14.9B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 77.4% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 0.81x PEG · 1.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) N/A ($8.17 Book/Sh · 11.5% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon NMR +20.89 pp
DCM: -26.75% · NMR: -5.86%
3M Horizon NMR +27.73 pp
DCM: -34.42% · NMR: -6.69%
6M Horizon NMR +27.73 pp
DCM: -34.42% · NMR: -6.69%
1Y Horizon NMR +27.73 pp
DCM: -34.42% · NMR: -6.69%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on DCM vs NMR. Trailing 12-month operating profitability (DCM N/A vs NMR 25.1%) and valuation multiples (DCM N/M vs NMR 11.4x Forward P/E) are benchmarked directly in Pillar 4 below.

DCM ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
NMR ADR TTM Benchmark FX-Normalized USD
TTM Revenue$14.9B
Gross Margin77.4%
Op. Margin25.1%
ROE / Fwd P/E11.5% · 11.4x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
DCM UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact DCM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
NMR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 30.7%
IV Percentile <1st %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact NMR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
DCM Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
NMR Moat Profile Scale & Operating Efficiency Moat
Capital Markets Operator
Competes within the Capital Markets value chain with $26.4B market capitalization and 25.1% operating margin.
OpEx & R&D Reinvestment 52.3% of Rev ($7.77B)
90D Engineering Disclosures 0 Published

Investor FAQ DCM vs NMR Key Questions & Quantitative Answers

As of Nov 20, 2026, Nomura Holdings, Inc (NMR) is the stronger overall head-to-head candidate over DCM (DCM) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). DCM carries a Unified Composite Score of 48.8/100 (HOLD) at $2.82 (N/M Forward P/E, N/A operating margin), whereas NMR carries 35.0/100 (SELL) at $8.51 (11.4x Forward P/E, 25.1% operating margin). Composite vs. Pillar Nuance: While DCM currently prints a higher short-term Unified Composite Score (48.8/100 HOLD vs. NMR 35.0/100 SELL), NMR captures the overall institutional head-to-head verdict (9–1 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (25.1% vs. N/A operating margin) and revenue trajectory (+17.9% vs. N/A YoY). Technical & Structure Timing Caution: DCM trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI N/A); meanwhile NMR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 30.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

NMR leads the Growth & Scale pillar: DCM posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with NMR at +17.9% YoY revenue growth and +13.6% YoY earnings growth on $14.9B TTM revenue (77.4% gross margin, 25.1% operating margin). On trailing 12-month operating scale, DCM generates N/A in USD-normalized revenue versus $14.9B for NMR. In operating R&D and SG&A reinvestment, DCM deploys N/A (0 90-day corporate R&D disclosures) versus 52.3% of Rev ($7.77B) (0 disclosures) for NMR.

NMR screens cheaper on headline valuation multiples. DCM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas NMR trades at 11.4x Forward P/E, 10.4x Trailing P/E, 0.81x PEG, and 1.8x EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DCM (N/A ROE) versus NMR (11.5% ROE) capital efficiency.

In options market volatility and institutional positioning, DCM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (N/A realized risk). By comparison, NMR carries 30.7% implied volatility (<1st %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.04β · 34% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.